- |||||||||| influenza vaccine (FLU-v) / ConserV Biosci, Imutex
Increase in IFNgamma secretion by PBMCs as correlate of cellular protection against influenza infection () - Mar 27, 2023 - Abstract #ISIRVFLU2023ISIRV_FLU_61;
P2b
Conclusion Quantification of the IFNgamma secretion by ELISA is a simple assay with the potential to become a correlate of protection for FLU-v. It is likely that different broad-spectrum influenza vaccines will require different correlates of protection and thresholds specific for their target and mode of action.
- |||||||||| influenza vaccine (FLU-v) / ConserV Biosci, Imutex
Trial completion, P2b data: A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine (clinicaltrials.gov) - Sep 5, 2017
P2b, N=170, Completed,
It is likely that different broad-spectrum influenza vaccines will require different correlates of protection and thresholds specific for their target and mode of action. Active, not recruiting --> Completed
- |||||||||| influenza vaccine (FLU-v) / ConserV Biosci, Imutex
Enrollment closed, P2b data, Enrollment change: A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine (clinicaltrials.gov) - Feb 8, 2017
P2b, N=170, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=222 --> 170
|
